Key Points
- Director Peter Farrell sold 2,000 ResMed shares on April 1 at $225 each, a transaction totaling $450,000, according to an SEC filing.
- ResMed beat quarterly expectations with EPS $2.81 vs. $2.68 and revenue of $1.42 billion vs. $1.40 billion, marking an 11% year‑over‑year revenue increase and a strong net margin of 27.53%.
- The company pays a quarterly dividend of $0.60 ($2.40 annually, 1.1% yield, 23.74% payout ratio), and analysts have an average rating of "Moderate Buy" with an average price target of $299.27.
ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter Farrell sold 2,000 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
ResMed Price Performance
NYSE RMD opened at $224.23 on Friday. The company has a market cap of $32.67 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 1.48 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32. The stock's fifty day moving average price is $247.09 and its 200 day moving average price is $253.74. ResMed Inc. has a 1 year low of $199.92 and a 1 year high of $293.81.
ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The medical equipment provider reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The company's quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.43 EPS. As a group, equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.
ResMed Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th were paid a $0.60 dividend. The ex-dividend date was Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.1%. ResMed's dividend payout ratio is presently 23.74%.
Institutional Investors Weigh In On ResMed
A number of institutional investors have recently added to or reduced their stakes in RMD. Terra Nova Asset Management LLC increased its holdings in ResMed by 0.6% in the 3rd quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider's stock valued at $2,136,000 after acquiring an additional 46 shares during the last quarter. NBT Bank N A NY boosted its holdings in shares of ResMed by 22.9% in the 3rd quarter. NBT Bank N A NY now owns 252 shares of the medical equipment provider's stock worth $69,000 after purchasing an additional 47 shares during the period. OFI Invest Asset Management increased its position in ResMed by 10.4% during the third quarter. OFI Invest Asset Management now owns 509 shares of the medical equipment provider's stock valued at $139,000 after acquiring an additional 48 shares during the last quarter. IMA Advisory Services Inc. raised its position in ResMed by 52.7% in the 3rd quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 48 shares during the period. Finally, Occidental Asset Management LLC increased its stake in ResMed by 3.0% in the 4th quarter. Occidental Asset Management LLC now owns 1,699 shares of the medical equipment provider's stock worth $409,000 after buying an additional 49 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. UBS Group reaffirmed a "buy" rating and set a $345.00 price objective on shares of ResMed in a research note on Friday, December 12th. Citigroup boosted their price objective on ResMed from $330.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, February 2nd. Wall Street Zen cut shares of ResMed from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. KeyCorp reaffirmed an "overweight" rating and issued a $302.00 price target on shares of ResMed in a report on Friday, January 30th. Finally, Wells Fargo & Company lifted their target price on shares of ResMed from $265.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $299.27.
Check Out Our Latest Stock Analysis on RMD
About ResMed
(
Get Free Report)
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
